Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
D R SnydmanS L Gorbach

Abstract

Antimicrobial resistance, including plasmid-mediated resistance, among Bacteroides fragilis group species is well documented. A 5-year (1990-1994) prospective, eight-center survey of 3,177 clinical isolates of Bacteroides species was undertaken to review trends in resistance, using the breakpoints for full and intermediate susceptibility established by the National Committee for Clinical Laboratory Standards. No documented resistance to either metronidazole or chloramphenicol was found in this survey. Among B. fragilis isolates virtually no resistance was seen to imipenem, meropenem, ampicillin/sulbactam, piperacillin/tazobactam, or ticarcillin/clavulanate. Significant increases in resistance among B. fragilis isolates to cefotetan, ceftizoxime, and clindamycin (p < .01) were noted. Resistance to cefoxitin remained unchanged. Among the non-fragilis species of the B. fragilis group, there was virtually no resistance to imipenem, meropenem, chloramphenicol, or metronidazole. The three beta-lactamase inhibitors had increasing levels of resistance, although 95%-98% of strains were susceptible (p < .05). There was a significant decline in cefoxitin, cefmetazole, and clindamycin activity over time against these strains (p <.01). Ther...Continue Reading

Citations

Jun 5, 2003·Journal of Microbiological Methods·Curtis J DonskeyLouis B Rice
Jan 10, 2002·Infectious Disease Clinics of North America·T F Smith
Jun 17, 2000·International Journal of Antimicrobial Agents·M E Falagas, E Siakavellas
May 18, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H Jorgensen, M J Ferraro
Jun 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M H NguyenD R Snydman
Sep 18, 2002·Antimicrobial Agents and Chemotherapy·D R SnydmanS L Gorbach
Aug 17, 2002·Antimicrobial Agents and Chemotherapy·Lee-Jene TengKwen-Tay Luh
Feb 26, 2004·Antimicrobial Agents and Chemotherapy·N V JacobusD R Snydman
Aug 12, 2009·Infectious Disease Clinics of North America·Joseph S Solomkin, John Mazuski
Apr 30, 1999·Mayo Clinic Proceedings·W C Hellinger, N S Brewer
Oct 3, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinUNKNOWN Infectious Diseases Society of America
Sep 3, 1999·Mayo Clinic Proceedings·M J Kasten
Jun 3, 2015·Antimicrobial Agents and Chemotherapy·Janessa M SmithSara E Cosgrove
Mar 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David W Hecht
Apr 21, 1999·The Journal of Laryngology and Otology·J M KlossekP Beutter
Aug 13, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D R SnydmanS L Gorbach
Aug 13, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D E RoeD W Hecht
Aug 13, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ellie J C Goldstein
Dec 26, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinJohn G Bartlett
Sep 26, 1997·Antimicrobial Agents and Chemotherapy·M E FalagasD R Snydman
Apr 4, 2000·Journal of Clinical Microbiology·L J TengK T Luh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.